Levetiracetam is a novel orally active antiepileptic drug with a unique preclinical profile. It
has a high therapeutic index and potential antiepileptogenic effects. Results of clinical trials …

Since 1989, eight new antiepileptic drugs (AEDs) have been licensed for clinical use.
Levetiracetam is the latest to be licensed and is used as adjunctive therapy for the treatment …

Purpose: To evaluate the efficacy and tolerability of levetiracetam (LEV, Keppra) as add‐on
therapy in patients with refractory partial seizures. Methods: In this European multicenter …

Purpose: To evaluate the efficacy and tolerability of levetiracetam (LEV) monotherapy in
selected patients with refractory partial seizures. Methods: In this multicenter, double‐blind …

The aim of the present review is to discuss the potential value of therapeutic drug monitoring
(TDM) of the newer antiepileptic drugs (AEDs) felbamate, gabapentin, lamotrigine …

The aim of the present paper is to provide information concerning the setting up and
interpretation of therapeutic drug monitoring (TDM) for anti-epileptic drugs. The potential …

The aim of this study was to determine the tolerability and efficacy of two oral regimens of
levetiracetam, 1000 mg and 2000 mg twice daily, as add-on treatment without titration in …

The pyrrolidone (2-oxopyrrolidine) family of chemicals has been the subject of research for
more than three decades. Experimental and clinical work first focused on their so-called …

The aim of this paper is to review a number of new antiepileptic agents (ie felbamate,
gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin and …

During the Past decade, nine new antiepileptic drugs (AEDs) namely, Felbamate,
Gabapentin, Levetiracetam, Lamotrigine, Oxcarbazepine, Tiagabine, Topiramate, Vigabatrin …